Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2015 1
2016 2
2017 3
2018 3
2019 3
2020 3
2021 7
2022 3
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease.
Lund T, Gundesen MT, Juul Vangsted A, Helleberg C, Haukås E, Silkjær T, Asmussen JT, Manuela Teodorescu E, Amdi Jensen B, Schmidt Slørdahl T, Nahi H, Waage A, Abildgaard N, Schjesvold F; Nordic Myeloma Study Group. Lund T, et al. Among authors: helleberg c. Blood Cancer J. 2024 Apr 15;14(1):65. doi: 10.1038/s41408-024-01046-2. Blood Cancer J. 2024. PMID: 38622134 Free PMC article. No abstract available.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
Potential value of pre-planned imaging of bone disease in multiple myeloma.
Gundesen MT, Asmussen JT, Schjesvold F, Vangsted AJ, Helleberg C, Haukås E, Silkjær T, Teodorescu EM, Jensen BA, Slørdahl TS, Nahi H, Waage A, Abildgaard N, Lund T; Nordic Myeloma Study Group. Gundesen MT, et al. Among authors: helleberg c. Blood Cancer J. 2023 Jul 7;13(1):105. doi: 10.1038/s41408-023-00880-0. Blood Cancer J. 2023. PMID: 37419876 Free PMC article. No abstract available.
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A, Brøndum RF, Johnsen HE, Mellqvist UH, Waage A, Gimsing P, Op Bruinink DH, van der Velden V, van der Holt B, Hansson M, Andersen NF, Frølund UC, Helleberg C, Schjesvold FH, Ahlberg L, Gulbrandsen N, Andreasson B, Lauri B, Haukas E, Bødker JS, Roug AS, Bøgsted M, Severinsen MT, Gregersen H, Abildgaard N, Sonneveld P, Dybkær K. Schmitz A, et al. Among authors: helleberg c. BMC Cancer. 2022 Feb 5;22(1):147. doi: 10.1186/s12885-022-09184-1. BMC Cancer. 2022. PMID: 35123422 Free PMC article.
The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy.
Szabo AG, Thorsen J, Iversen KF, Levring MB, Preiss B, Helleberg C, Breinholt MF, Hermansen E, Gjerdrum LMR, Bønløkke ST, Nielsen K, Kjeldsen E, Teodorescu EM, Dokhi M, Kurt E, Strandholdt CN, Andersen MK, Vangsted AJ. Szabo AG, et al. Among authors: helleberg c. Am J Hematol. 2022 Mar 1;97(3):E117-E120. doi: 10.1002/ajh.26449. Epub 2021 Dec 29. Am J Hematol. 2022. PMID: 34967035 Free article. No abstract available.
The real-world outcomes of multiple myeloma patients treated with daratumumab.
Szabo AG, Klausen TW, Levring MB, Preiss B, Helleberg C, Breinholt MF, Hermansen E, Gjerdrum LMR, Bønløkke ST, Nielsen K, Kjeldsen E, Iversen KF, Teodorescu EM, Dokhi M, Kurt E, Strandholdt C, Andersen MK, Vangsted AJ. Szabo AG, et al. Among authors: helleberg c. PLoS One. 2021 Oct 13;16(10):e0258487. doi: 10.1371/journal.pone.0258487. eCollection 2021. PLoS One. 2021. PMID: 34644367 Free PMC article.
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.
Gregersen H, Peceliunas V, Remes K, Schjesvold F, Abildgaard N, Nahi H, Andersen NF, Vangsted AJ, Klausen TW, Helleberg C, Carlson K, Frølund UC, Axelsson P, Stromberg O, Blimark CH, Crafoord J, Tsykunova G, Eshoj HR, Waage A, Hansson M, Gulbrandsen N. Gregersen H, et al. Among authors: helleberg c. Eur J Haematol. 2022 Jan;108(1):34-44. doi: 10.1111/ejh.13709. Epub 2021 Oct 11. Eur J Haematol. 2022. PMID: 34536308 Free PMC article. Clinical Trial.
Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.
Højholt KL, Gregersen H, Szabo AG, Klausen TW, Levring MB, Preiss B, Helleberg C, Breinholt MF, Hermansen E, Rahbek Gjerdrum LM, Bønløkke ST, Nielsen K, Kjeldsen E, Iversen KF, Teodorescu EM, Kurt E, Strandholdt C, Andersen MK, Vangsted AJ. Højholt KL, et al. Among authors: helleberg c. Hematol Oncol. 2021 Oct;39(4):521-528. doi: 10.1002/hon.2906. Epub 2021 Aug 2. Hematol Oncol. 2021. PMID: 34342035
Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio.
Szabo AG, Klausen TW, Abildgaard N, Gregersen H, Silkjær T, Pedersen PT, Pedersen RS, Helleberg C, Hermansen E, Schnack BI, Vangsted AJ. Szabo AG, et al. Among authors: helleberg c. Blood Cancer J. 2021 Apr 7;11(4):70. doi: 10.1038/s41408-021-00460-0. Blood Cancer J. 2021. PMID: 33828079 Free PMC article. No abstract available.
24 results